Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels

por Sillerud LO
Publicado 2016

Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach

por Hanane Lahnif, Tilmann Grus, Stefanie Pektor, Lukas Greifenstein, Mathias Schreckenberger, Frank Rösch
Publicado 2021

Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer

por Wu M, Wang Y, Wang YR, Zhang MB, Luo YK, Tang J, Wang ZG, Wang D, Hao L, Wang ZB
Publicado 2017

Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

por Xing Zhou, Xiao Jiang, Luzhou Liu, Xiaoxiong Wang, Chuan Li, Yutang Yao, Ying Kou, Jiaqi Shen, Taipeng Shen, Zeng Li, Shengke Yang, Shukui Zhou, Hong Liao, Zhifu Luo, Xiaoai Wu, Shirong Chen, Zhuzhong Cheng
Publicado 2022

Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles

por Fan X, Guo Y, Wang L, Xiong X, Zhu L, Fang K
Publicado 2016

Targeted Nanobubbles Carrying Indocyanine Green for Ultrasound, Photoacoustic and Fluorescence Imaging of Prostate Cancer

por Wang Y, Lan M, Shen D, Fang K, Zhu L, Liu Y, Hao L, Li P
Publicado 2020

Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer—A New Diagnostic and Therapeutic Target?

por Sabine Wächter, Pietro Di Fazio, Elisabeth Maurer, Jerena Manoharan, Corinna Keber, Andreas Pfestroff, Damiano Librizzi, Detlef K. Bartsch, Markus Luster, Friederike Eilsberger
Publicado 2021

PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook

por Maximilian A. Kirchner, Adrien Holzgreve, Matthias Brendel, Michael Orth, Viktoria C. Ruf, Katja Steiger, Dennis Pötter, Lukas Gold, Marcus Unterrainer, Marcus Unterrainer, Lena M. Mittlmeier, Enio Barci, Roland E. Kälin, Rainer Glass, Rainer Glass, Simon Lindner, Lena Kaiser, Jessica Maas, Louisa von Baumgarten, Harun Ilhan, Claus Belka, Claus Belka, Johannes Notni, Peter Bartenstein, Peter Bartenstein, Kirsten Lauber, Kirsten Lauber, Nathalie L. Albert, Nathalie L. Albert
Publicado 2021

Initial Experience of Clinical Use of [^99mTc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study

por Jarosław B. Ćwikła, Marek Roslan, Iwona Skoneczna, Monika Kempińska-Wróbel, Michał Maurin, Wojciech Rogowski, Barbara Janota, Anna Szarowicz, Piotr Garnuszek
Publicado 2021

Design and synthesis of a new conjugate of a tris(3-hydroxy-4-pyridinone) chelator (KC18) for potential use as gallium-68-labeled prostate-specific membrane antigen (PSMA) radiopha...

por Xu Zhou, Lin-Lin Dong, Yuying Li, Meng-Chao Cui, Lang-Tao Shen
Publicado 2021

Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence

por Sophie Knipper, Sabine Riethdorf, Stefan Werner, Derya Tilki, Markus Graefen, Klaus Pantel, Tobias Maurer
Publicado 2021